Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
<< anterior 21 a 40 de 77 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Boyd I. Saxagliptin and pancreatitis. Signal 2011:10-2. [Ref.ID 91691]
22. Cita con resumen
Tengstrand M, Star K, van Puijenbroek EP, Hill R. Alopecia in association with lamotrigine use: an analysis of individual case safety reports in a global database. Drug Saf 2010;33:653-8. [Ref.ID 88991]
23. Cita con resumen
Melhus H, Snellman G, Gedeborg R, Byberg L, Berglund L, Mallmin H, Hellman P, Blomhoff R, Hagström E, Arnlöv J, Michaëlsson K. Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden. J Clin Endocrinol Metab 2010;95:2630-3. [Ref.ID 88592]
24. Cita con resumen
De Backer TLM, Stichele RHV, Van Bortel LM. Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication. Drug Saf 2009;32:283-91. [Ref.ID 85762]
25.Tiene citas relacionadas Cita con resumen
Kao D. What can we learn from drug marketing efficiency?. BMJ 2009;338:141-4. [Ref.ID 85028]
26. Cita con resumen
Anónimo. Drotrecogin alfa - Thrombosis?. WHO Pharmaceuticals Newsletter 2008;5:13-5. [Ref.ID 84860]
27. Cita con resumen
Clark DWJ, Coulter DM, Besag FMC. Randomized controlled trials and assessment of drug safety. Drug Saf 2008;31:1057-61. [Ref.ID 84722]
28. Cita con resumen
Jacobs P. Oxaliplatin and cardiotoxicity. Signal 2008:10-4. [Ref.ID 83385]
29. Cita con resumen
Clark D. Ezetimibe and fatty liver. Signal 2008:6-7. [Ref.ID 83384]
30. Cita con resumen
Anónimo. Oseltamivir. Label to include information on neuropsychiatric events. USA. WHO Pharmaceuticals Newsletter 2008;2:4. [Ref.ID 83225]
31. Cita con resumen
Pirmohamed M, Atuah KN, Dodoo ANO, Winstanley P. Pharmacovigilance in developing countries. BMJ 2007;335:462. [Ref.ID 81053]
32. Cita con resumen
Sukkar E. BMJ and The Lancet criticised by WHO head of drug safety. Scrip 2007;3263/64:20. [Ref.ID 80195]
33.
Hugman B. The Erice declaration: the critical role of communication in drug safety. Drug Saf 2006;29:91-3. [Ref.ID 77460]
34. Cita con resumen
Gibson L. Adverse reaction reports may be vulnerable to manipulation. BMJ 2005;330:1287. [Ref.ID 73996]
35.
36.Tiene citas relacionadas Cita con resumen
Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005;365:482-7. [Ref.ID 72679]
37.Tiene citas relacionadas Cita con resumen
Ruchkin V, Martin A. SSRIs and the developing brain. Lancet 2005;365:451-3. [Ref.ID 72675]
38. Cita con resumen
Meyboom RHB, Edwards IR. Rosuvastatin and the statin wars - the way to peace. Lancet 2004;364:1997-9. [Ref.ID 72041]
39.
van Grrotheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf 2004;13:457-64. [Ref.ID 70834]
40.
Stahl M, Lindquist M, Edwards IR, Brown EG. Introducing triage logic as a new strategy for the detection of signals in the WHO Drug Monitoring Database. Pharmacoepidemiol Drug Saf 2004;13:355-63. [Ref.ID 70402]
Seleccionar todas
 
<< anterior 21 a 40 de 77 siguiente >>